A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

This is a post-marketing safety surveillance study in Korea for ozanimod (brand name Zeposia), a medication for adults with moderate to severe active ulcerative colitis — a type of inflammatory bowel disease causing ongoing gut inflammation. The goal is to track real-world safety data after approval. **You may be eligible if...** - You are 19 or older (Korean adult) - You have moderate to severe active ulcerative colitis - Your doctor has prescribed ozanimod according to the approved Korean label - You have signed informed consent voluntarily **You may NOT be eligible if...** - You are being prescribed ozanimod for an unapproved use in Korea - You have a medical contraindication to ozanimod according to the Korean prescribing information Talk to your doctor to see if this trial is right for you.